|MDACC Study No:||BTTC08-01-MDA (clinicaltrials.gov NCT No: NCT00720356)|
|Title:||A Phase II study of Bevacizumab and Erlotinib after Radiation Therapy and Temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter methylation |
|Principal Investigator:||John DeGroot|
|Treatment Agent:||Bevacizumab; Erlotinib; Temozolomide|
|Study Description:||The goal of this clinical research study is to learn if the combination of |
bevacizumab and erlotinib after treatment with temozolomide and radiation
therapy will help to control glioblastoma when a certain gene called MGMT is
turned "on". The safety of this drug combination will also be studied.